"Tracking Baker Brothers Portfolio – Q2 2023 Update"
"….….….This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory  filed on 8/14/2023. The 13F portfolio value decreased from $18.38B to $17.28B. Although there are ~120 positions in the 13F portfolio, the holdings are concentrated among a few large stakes. There are 16 positions that are significantly large (more than 0.5% of the portfolio each) and they are the focus of this article. The largest five stakes are Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. They add up to ~83% of the portfolio. Please visit our  series to get an idea of their investment philosophy and our previous  for the fund’s moves during Q1 2023.Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. Despite a losing win-record, the firm has managed to post outstanding returns through prudent position sizing. As a percentage of AUM, allocation to the highest conviction picks can be very high at over 30%. Over the years, the firm had a number of home runs as the invested firms got acquired at huge premiums. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), Alexion (acquired by AstraZeneca), Global Blood Therapeutics (acquired by Pfizer), and ChemoCentryx (acquired by Amgen).Stake Increases:Incyte Corporation (INCY): INCY was already a 1.67M share stake in their first 13F filing in Q2 2003. The stake had roughly doubled by 2006. The 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices in the high single digits. Major activity in the last decade follows. Q3 2015 saw a ~30% stake increase at prices between ~$105 and ~$130. Q1 2016 saw another ~20% stake increase at prices between ~$65 and ~$100. That was followed with a ~45% stake increase in Q1 2017 at prices between ~$100 and ~$150. There was a ~13% stake increase over the two quarters through Q1 2022 at prices between ~$63 and ~$80. The stock currently trades at $65.25, and it is a top-three stake at ~13% of the portfolio. There was a marginal increase in the last two quarters.Note: Baker Brothers controls ~16.3% of the business.ACADIA Pharmaceuticals (ACAD): The ~6% ACAD stake was established in the 2012-2013 timeframe at very low prices. The last major activity was in Q4 2018 when there was a ~40% stake increase at prices between ~$14 and ~$22. The stock currently trades at ~$27. There was a marginal increase in the last two quarters.Note: They have a ~26% ownership stake in the business.AbCellera Biologics (ABCL): ABCL had an IPO in December 2020. Shares started trading at ~$49 and currently go for $5.80. Baker Brothers’ stake goes back to funding rounds prior to the IPO. There was a ~60% stake increase this quarter at prices between $5.66 and $7.60.Kymera Therapeutics (KYMR), and Roivant Sciences (ROIV): These two very small stakes saw substantial increases this quarter. The 0.58% KYMR stake was increased by ~50% at prices between ~$22.50 and ~$35. It is now below that range at $19.59. ROIV is a 0.55% position that was doubled this quarter at prices between ~$7 and ~$10. It now trades above that range at $11.58.Stake Decreases:Seagen Inc. (SGEN): SGEN is currently the largest position by far at ~50% of the entire portfolio. It is a very long-term stake that has been in the portfolio for over fifteen years. The position was built to ~20.5M shares in the 2004-2011 timeframe at prices between low-single-digits and low-20s. Q1 2014 to Q1 2016 saw another stake doubling at prices between ~$30 and ~$55. There was a ~5% trimming this quarter. The stock currently trades at ~$207.Note: They have ~25% ownership stake in the business. In March, Pfizer (PFE) agreed to acquire Seagen in a $229 per share all-cash deal.Kept Steady:BeiGene Limited (BGNE): The large (top three) ~12% BGNE stake has been in the portfolio since their US listing in Q1 2016. Shares started trading at ~$24 and currently goes for ~$211. Q4 2016 saw a stake doubling at prices between ~$28 and ~$36. H1 2018 saw the stake built from ~3.8M shares to ~12M shares at prices between ~$100 and ~$215. Since then, the activity has been minor.Note: Baker Brothers controls ~13% of the business.Madrigal Pharmaceuticals (MDGL): The last major activity in MDGL was a ~30% stake increase in Q1 2020 at prices between ~$65 and ~$90. The stock is now at ~$178. There was a minor ~3% stake increase during Q4 2022.Note: Baker Brothers controls ~9% of Madrigal Sciences.BioMarin Pharmaceutical (BMRN): A small stake in BMRN was first purchased in 2006 but was eliminated the following year at higher prices. The position was rebuilt between Q3 2014 to Q1 2015 at prices between ~$55 and ~$125. 2017 saw a ~60% stake increase at prices between ~$80 and ~$95. The last quarter saw the position reduced by ~50% at prices between ~$88 and ~$117. The stock is now at ~$94, and the stake is at 1.91% of the portfolio.Immunocore Holdings plc (IMCR): IMCR is a very small 0.87% of the portfolio position that was kept steady this quarter. They have a ~10% ownership stake in the business.Kodiak Sciences (KOD): KOD is now a small 0.69% of the portfolio position. The original stake goes back to funding rounds prior to its Q4 2018 IPO. Shares started trading at ~$10 and currently goes for $2.25. The last significant activity was in Q4 2019 which saw a ~20% stake increase at prices between ~$14.50 and ~$76. They have a ~30% ownership stake in the business. Q2 2022 saw a ~9% stake increase.Note: In December 2019, Baker Brothers struck a deal for a capped 4.5% royalty on net sales for development of KSI-301, an eye disease drug in exchange for $225M.Akero Therapeutics (AKRO): AKRO is a 0.64% of the portfolio stake built during Q3 2022 at prices between ~$10 and ~$34. The stock currently trades well above that range at $49.71.Note: They have a ~5% ownership stake in the business.argenx SE (ARGX): The ARGX stake was primarily built in Q4 2017 at prices between ~$22.50 and ~$63. There was a ~10% stake increase in Q1 2021 at prices between ~$268 and ~$380. Q3 2022 saw a ~75% reduction at prices between ~$343 and ~$396. The stock currently trades at ~$503 and the stake is at 0.63% of the portfolio.Rhythm Pharma (RYTM): The small 0.62% of the portfolio stake in RYTM saw a ~47% stake increase during Q2 2022 at prices between $4.30 and $30.85 and the stock is now at ~$26. The last two quarters saw minor increases.Note: They have a ~11.5% ownership stake in Rhythm Pharma.Replimune Group (REPL): The very small 0.62% REPL stake saw a ~18% increase during Q4 2022 at prices between ~$17 and ~$28. The stock is now at ~$21.Note: they have a ~10% ownership stake in the business.BioCryst Pharmaceuticals (BCRX): BCRX is a very long-term stake that has been in the portfolio since 2004. It is still a small position at 0.52% of the portfolio. The last major activity was in 2019 when Q2 to Q4 saw a one-third selling at prices between ~$1.60 and ~$8.70. The stock currently trades at $6.94.Note: Baker Brothers controls ~10% of BioCryst Pharmaceuticals.Note: Baker Brothers has significant ownership stakes in the following businesses – 2seventy Bio (TSVT), Achilles Therapeutics (ACHL), Aeglea BioTherapeutics (AGLE), Aerovate (AVTE), Aravive Inc. (ARAV), Biomea Fusion (BMEA), Cabaletta Bio (CABA), Cerus Pharma (CERS), HOOKIPA Pharma (HOOK), Immatics (IMTX), Kala Pharma (KALA), Neoleukin Therapeutics (NLTX), Nurix Therapeutics (NRIX), Opthea Ltd. (OPT), Talis Biomedical (TLIS), and TScan Therapeutics (TCRX).The spreadsheet below highlights changes to Baker Brothers’ 13F holdings in Q2 2023:Source: John Vincent. Data constructed from Baker Brothers’ 13F filings for Q1 2023 and Q2 2023.Regulatory filings from 3/23/2023 to 5/24/2023: 13D/A – 5/5 – BGNE – 152.5M shares – 11.2% of business. 13D, Form 3 – 5/5 – BLCM – Bellicum – 2.2M shares (~20% of business – includes ownership based on warrants to buy). 13D/A – 5/3 – SGEN – 44.62M shares – 23.8% of business, Form 4s – 5/3 – minor. Form 4 – 4/4, 3/31 – IGMS – minor - ~2.90M shares. Form 4 – 4/4 – INCY - minor."